Details for Patent: 8,334,265

Which drugs does patent 8,334,265 protect, and when does it expire?

Patent 8,334,265 protects SCENESSE and is included in one NDA.

This patent has twenty-three patent family members in sixteen countries.

Summary for Patent: 8,334,265

Title:	Method of treatment of photodermatoses
Abstract:	This invention relates to a method for prophylactic or therapeutic treatment of photodermatoses that are caused or exacerbated by or associated with UVR exposure in a subject, particularly a human subject, which comprises the step of administering to said subject an amount of an alpha-MSH analogue effective to reduce the photosensitivity of the skin of the subject.
Inventor(s):	Philippe Wolgen
Assignee:	Clinuvel Pharmaceuticals Ltd
Application Number:	US12/438,990
Patent Claim Types: see list of patent claims	Use;

US Patent 8,334,265: Scope, Claims, Expiration, Orange Book Status, and Afamelanotide Patent Landscape

US Patent 8,334,265 covers the use of afamelanotide, chemically identified as [Nle4, D-Phe7]-alpha-melanocyte stimulating hormone, to reduce UV-related photosensitivity in humans with photodermatoses. The independent claim covers the treatment concept broadly. Dependent claims specify erythropoietic photoporphyria, solar urticaria, and polymorphous light eruption.

The patent is a method-of-treatment patent. It does not, based on the supplied claims, claim afamelanotide as a molecule, a particular implant formulation, a manufacturing process, or a dosing schedule. Its commercial relevance is highest for Scenesse, Clinuvel Pharmaceuticals' afamelanotide product approved in the United States for erythropoietic protoporphyria (EPP).

What does US Patent 8,334,265 claim?

US Patent 8,334,265 claims administration of afamelanotide to a human patient with a UV-associated photodermatosis to reduce skin photosensitivity.[1]

Claim structure

Claim	Type	Subject matter
1	Independent method claim	Administering [Nle4, D-Phe7]-alpha-MSH to a human suffering from a UV-caused, UV-exacerbated, or UV-associated photodermatosis in an amount effective to reduce photosensitivity
2	Dependent method claim	Claim 1 where the condition is EPP
3	Dependent method claim	Claim 1 where the condition is solar urticaria
4	Dependent method claim	Claim 1 where the condition is polymorphous light eruption

The active ingredient is afamelanotide. It is a synthetic analog of alpha-melanocyte-stimulating hormone that activates melanocortin receptors and promotes eumelanin production.

Key limitations in claim 1

A product or treatment must satisfy each material limitation of claim 1:

1. The patient must be human.
2. The patient must suffer from a photodermatosis.
3. The photodermatosis must be caused, exacerbated, or associated with UV radiation exposure.
4. The administered compound must be [Nle4, D-Phe7]-alpha-MSH.
5. The administered amount must be effective to reduce skin photosensitivity.

The claim does not expressly require:

• A subcutaneous implant;
• A specified dose;
• A specified treatment interval;
• A particular pharmaceutical excipient;
• A particular level of melanin production;
• A specific reduction in phototoxic reactions;
• FDA-approved use;
• Treatment exclusively during periods of UV exposure.

The phrase "effective to reduce the photosensitivity" is a functional limitation. In an infringement analysis, the relevant question would be whether the administered amount produces the claimed therapeutic result, assessed through clinical or technical evidence.

How broad is the independent claim?

Claim 1 is materially broader than the dependent EPP claim. It covers three causal relationships between the disease and UV exposure: caused by UV radiation, exacerbated by UV radiation, or associated with UV radiation.

That language potentially reaches more than inherited or metabolic photodermatoses. It can encompass conditions in which UV exposure worsens symptoms, even if UV exposure is not the primary cause of the disease. The claim is therefore not limited to EPP.

The claim is narrower in other respects. It requires the specific peptide analog afamelanotide. A different melanocortin agonist, a natural alpha-MSH product, or a nonpeptide melanocortin receptor agonist would not literally satisfy the active-agent limitation, although equivalents and prosecution-history estoppel could affect an analysis under the doctrine of equivalents.

Claim construction issues

Several terms are likely to matter in litigation or licensing diligence:

Claim term	Commercial significance
"Photodermatoses"	Determines which diseases fall within the claimed disease class
"Caused or exacerbated by or associated with UVR exposure"	Broadens the claim beyond diseases directly caused by UV radiation
"An amount effective"	Links infringement to the therapeutic result and may require dose-response evidence
"Reduce the photosensitivity"	Defines the claimed clinical effect rather than a manufacturing or formulation property
"[Nle4, D-Phe7]-alpha-MSH"	Identifies afamelanotide as the required active agent
"Administering to said subject"	Focuses infringement on treatment conduct rather than sale of the active ingredient alone

The patent does not appear, from the supplied claims, to cover afamelanotide in every use. Administration for tanning, pigmentary disorders, sexual dysfunction, or another non-UV-related condition would fall outside these claims unless the claimed photodermatosis and photosensitivity limitations were also met.

What diseases are protected by US Patent 8,334,265?

The patent expressly identifies EPP, solar urticaria, and polymorphous light eruption.

Erythropoietic photoporphyria

EPP is the most commercially significant indication. It is a rare inherited disorder involving accumulation of protoporphyrin and severe photosensitivity. Patients can develop painful phototoxic reactions after exposure to visible light and UV radiation.

Claim 2 covers afamelanotide treatment of EPP, provided the limitations of claim 1 are met. The claim does not require the patient to have a particular genetic mutation, a specified protoporphyrin level, or a particular disease severity.

The FDA approved Scenesse for the prevention of phototoxicity in adult patients with EPP in October 2019.[2] The approved product is a controlled-release subcutaneous implant administered by a healthcare professional.

Solar urticaria

Claim 3 covers treatment of solar urticaria. Solar urticaria is an inducible photodermatosis characterized by urticarial reactions after exposure to sunlight or other relevant radiation.

FDA approval of Scenesse for EPP does not automatically establish FDA approval for solar urticaria. The patent claim and the regulatory indication are separate questions. A treatment can fall within the patent claim while remaining off-label from an FDA labeling perspective.

Polymorphous light eruption

Claim 4 covers polymorphous light eruption, a common photodermatosis involving delayed inflammatory eruptions after sun exposure.

As with solar urticaria, the patent claim is broader than the current FDA-approved EPP indication. Commercial use for polymorphous light eruption would raise both patent and regulatory questions, including whether the treatment is promoted for an unapproved use.

What is the patent expiration date for US Patent 8,334,265?

US Patent 8,334,265 is generally associated with a 2027 expiration date based on its relevant US patent term, subject to the official term calculation, patent term adjustment, terminal disclaimers, and any applicable patent term extension.[1]

Item	Data
Patent	US 8,334,265 B2
Patent type	Utility patent
Core subject	Afamelanotide treatment of UV-related photodermatoses
Patent holder or assignee	Clinuvel Pharmaceuticals Limited
Relevant product	Scenesse
Expected nominal expiration	2027, subject to official USPTO term calculation
Core commercial indication	EPP
Claim category	Method of treatment

The patent does not create perpetual exclusivity for afamelanotide. After expiration, a competitor could still face other valid patents covering the product, implant, formulation, manufacturing process, or a different approved method of use.

What is the Orange Book status of US Patent 8,334,265?

The FDA approved Scenesse under NDA 207795 for adult patients with EPP.[2] Orange Book-listed patents can create an ANDA litigation pathway when a generic applicant makes a Paragraph IV certification against a listed patent.[3]

The practical Orange Book questions are:

• Whether US Patent 8,334,265 is listed for the relevant Scenesse NDA;
• Which FDA use code is associated with the patent;
• Whether the listed use corresponds to EPP;
• Whether the patent remains unexpired;
• Whether the proposed generic labeling includes the patented use.

An Orange Book listing does not mean that every use of afamelanotide is protected. It ties the listed patent to the approved drug and the use code submitted by the NDA holder.

Paragraph IV implications

A generic applicant seeking approval before patent expiration may submit a Paragraph IV certification asserting that the listed patent is invalid, unenforceable, or not infringed.[3] The NDA holder or patent owner may then bring an action under 35 U.S.C. § 271(e)(2).

A timely patent suit can trigger a statutory stay of FDA approval, generally for up to 30 months, subject to statutory exceptions and court developments.[4]

For a method-of-use patent, the generic applicant may attempt a section viii statement that it will omit the patented indication from its labeling. The viability of that strategy depends on:

• The precise Orange Book use code;
• Whether the generic label can omit EPP treatment;
• Whether the remaining label encourages the patented method;
• Whether the product has substantial noninfringing uses;
• Whether prescribing and administration conduct would still create induced-infringement exposure.

A skinny-label strategy is more difficult where the patented use is the principal or only commercially meaningful use of the product.

Which companies are challenging US Patent 8,334,265?

No publicly established Paragraph IV challenger, district-court infringement judgment, or settlement involving US Patent 8,334,265 is identified in the materials available for this analysis.

The competitive threat is therefore better characterized as an entry-risk assessment rather than an identified litigation campaign. A challenger would likely need to address:

1. Claim construction for "photodermatoses" and "reduce the photosensitivity";
2. Written description and enablement;
3. Obviousness based on alpha-MSH analogs, melanocortin biology, and photodermatosis treatment data;
4. Anticipation by earlier clinical or patent disclosures;
5. The scope of any Orange Book listing;
6. Whether an alternative label could avoid induced infringement.

How strong is the patent estate for afamelanotide?

US Patent 8,334,265 has meaningful value because it aligns with the principal approved indication for Scenesse. Its strength is indication-specific rather than molecule-wide.

Strengths

• It covers the active ingredient used in Scenesse.
• It covers a therapeutic result directly tied to the EPP product value proposition.
• The independent claim reaches multiple UV-related photodermatoses.
• Claim 2 expressly addresses EPP, the FDA-approved indication.
• The claim does not require a narrow dosing schedule or a particular implant design.
• The method claim can be relevant to generic treatment conduct even when the generic product itself is chemically identical.

Limitations

• It is not a composition-of-matter claim.
• It does not prevent all manufacture or sale of afamelanotide.
• It does not necessarily cover non-UV-related uses.
• The claim requires proof of the treatment method and clinical effect.
• A generic may seek a label that omits patented uses.
• Validity may be challenged using prior art concerning melanocortin agonists and photoprotection.
• Patent expiration ends the principal exclusionary right unless another valid patent remains.

The estate should therefore be classified as a targeted clinical-use estate, not a complete product monopoly.

What formulation patents protect Scenesse?

US Patent 8,334,265, based on the supplied claims, does not protect a specific formulation or implant. It protects the act of using afamelanotide for the claimed photodermatoses.

Formulation and delivery-system protection would normally arise from separate patent families directed to:

• Controlled-release implants;
• Peptide stability;
• Biodegradable polymer matrices;
• Implant dimensions and drug loading;
• Release-rate profiles;
• Sterilization and manufacturing conditions;
• Packaging and storage;
• Administration protocols.

Those patents can materially extend practical market protection after a method patent expires. They must be assessed separately from US 8,334,265. The existence, status, and Orange Book relevance of any later formulation patent cannot be inferred from the four claims supplied.

What is the FDA exclusivity timeline for Scenesse?

Date	Event
October 8, 2019	FDA approval of Scenesse for adult patients with EPP
October 2019	Orphan-drug exclusivity period begins for the approved EPP indication
Approximately October 2026	Seven-year orphan-drug exclusivity period expected to end, subject to the statutory record
2027	Nominal expiration period associated with US Patent 8,334,265

Orphan-drug exclusivity is indication-specific. It can block FDA approval of the same drug for the same disease during the exclusivity period, subject to statutory exceptions. It does not prevent approval of a different drug or necessarily block all off-label use.

Regulatory exclusivity and patent exclusivity operate independently:

• Orphan exclusivity restricts FDA approval of the same drug for the same rare disease.
• Patent exclusivity can restrict making, using, selling, offering to sell, or importing the patented invention.
• FDA approval does not determine patent validity.
• Patent expiration does not eliminate regulatory requirements for approval.

The product is a small-molecule peptide drug, not a biologic. Biosimilar pathway risk under the Public Health Service Act is therefore not the central entry issue. A competitor would more likely pursue an ANDA, a 505(b)(2) application, or another pathway depending on product characterization and the proposed dosage form.

What patent litigation affects afamelanotide?

The principal litigation risk around US Patent 8,334,265 would arise from a generic or alternative afamelanotide sponsor filing an ANDA or 505(b)(2) application before expiration.

Potential causes of action include:

• ANDA-based infringement under 35 U.S.C. § 271(e)(2);
• Direct infringement through administration of the patented treatment;
• Induced infringement through labeling, promotion, or instructions;
• Declaratory judgment litigation;
• Invalidity counterclaims;
• Settlement negotiations involving launch timing, label restrictions, or authorized-generic arrangements.

No settlement agreement or final infringement judgment is established here for this patent. A future settlement could provide an earlier launch date without invalidating the patent or establishing that the claims are strong.

How does US Patent 8,334,265 compare with a molecule or formulation patent?

Patent category	What it protects	Relevance to Scenesse
Composition-of-matter patent	Afamelanotide molecule or defined chemical entity	Broadest product protection, but generally expires earlier if based on original discovery
Method-of-treatment patent	Use of afamelanotide for UV-related photodermatoses	Directly protects clinical use, especially EPP
Formulation patent	Implant, excipient, release profile, or stability system	Can complicate substitution with a different dosage form
Manufacturing patent	Synthesis, purification, sterilization, or implant production	Can increase technical barriers without blocking all alternative processes
Regulatory exclusivity	FDA approval for a defined disease and product	Can delay approval independently of patent scope

US 8,334,265 is strongest when the competing product seeks approval for EPP and relies on labeling that directs physicians to use afamelanotide to reduce photosensitivity. It is weaker against a product designed around a noninfringing indication, a different active agent, or a genuinely different therapeutic objective.

What generic launch scenarios exist?

Launch before patent expiration

A pre-expiration launch would usually require one of the following:

• A successful Paragraph IV challenge;
• A court ruling of noninfringement or invalidity;
• A settlement permitting entry;
• A license from the patent holder;
• A product label that avoids the listed patented use.

Launch at patent expiration

Entry at or after expiration reduces patent litigation risk for the expired claims. Remaining barriers could include other unexpired formulation, manufacturing, or use patents and FDA approval requirements.

505(b)(2) entry

A 505(b)(2) applicant could seek approval for a modified afamelanotide product, such as a different delivery system or dosage form. This route could create a separate patent dispute and would not automatically eliminate method-of-use infringement risk.

Authorized or licensed entry

Clinuvel could permit entry through a license, supply arrangement, or authorized-generic structure. No such agreement is established for US Patent 8,334,265 in the available record.

What geographic coverage does the patent provide?

US Patent 8,334,265 provides rights limited to the United States. It does not directly block treatment, sale, or manufacture in Europe, Australia, Japan, or other jurisdictions.

Clinuvel's international protection would depend on corresponding national patents and their individual:

• Grant status;
• Claim scope;
• Expiration dates;
• Patent term adjustments or extensions;
• Litigation history;
• Regulatory linkage;
• Orphan-drug exclusivity.

The US patent should not be treated as evidence that equivalent claims remain enforceable worldwide.

Key Takeaways

• US Patent 8,334,265 is a method-of-treatment patent for afamelanotide in UV-related photodermatoses.
• Claim 1 is the central claim and covers administration to a human patient to reduce photosensitivity.
• Claims 2 through 4 specifically cover EPP, solar urticaria, and polymorphous light eruption.
• EPP is the commercially important claim because Scenesse is FDA-approved for adult EPP patients.
• The patent does not, on the supplied claims, cover afamelanotide as a molecule, a particular implant, or a manufacturing process.
• The patent is generally associated with expiration in 2027, subject to the official USPTO term calculation.
• Scenesse received FDA approval in 2019, and orphan-drug exclusivity is expected to run for seven years from approval for the EPP indication.
• A generic challenge would likely involve Paragraph IV, section viii labeling, or a 505(b)(2) strategy.
• Biosimilar competition is not the primary risk because afamelanotide is not being analyzed as a biologic subject to the standard biosimilar pathway.
• The patent estate is clinically aligned with the approved product but does not create a molecule-wide monopoly.

FAQs

Does US Patent 8,334,265 cover all uses of afamelanotide?

No. It covers administration for UV-related photodermatoses where the treatment reduces photosensitivity. Non-UV-related uses fall outside the express claim language.

Can a generic sell afamelanotide after omitting EPP from its label?

Potentially, but the outcome depends on the Orange Book use code, the proposed labeling, actual promotion, and whether the remaining instructions induce use of the patented EPP method.

Is Scenesse protected by a biosimilar patent strategy?

No. Scenesse is an afamelanotide peptide drug, not a conventional biologic subject to the standard biosimilar approval framework. The principal US competition routes are likely ANDA or 505(b)(2), depending on the product.

Does the patent cover the Scenesse implant itself?

Not based on the supplied claims. The claims cover the therapeutic method. A separate patent would be needed to protect the implant composition, geometry, release profile, or manufacturing process.

Does FDA approval for EPP prove that claim 2 is valid?

No. FDA approval and patent validity are separate legal determinations. Approval confirms regulatory authorization for the product and indication; it does not resolve novelty, obviousness, enablement, written description, or infringement issues.

References

1. United States Patent and Trademark Office. (2012). US Patent No. 8,334,265 B2: Use of alpha-melanocyte stimulating hormone analogues in the treatment of photodermatoses.
2. U.S. Food and Drug Administration. (2019). Scenesse (afamelanotide) prescribing information.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
4. United States Code. (2024). 35 U.S.C. §§ 271(e)(2), 271(e)(4), and 355(j).

Drugs Protected by US Patent 8,334,265

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Clivunel Inc	SCENESSE	afamelanotide	IMPLANT;SUBCUTANEOUS	210797-001	Oct 8, 2019		RX	Yes	Yes	8,334,265					INCREASE PAIN-FREE LIGHT EXPOSURE IN ADULT PATIENTS WITH A HISTORY OF PHOTOTOXIC REACTIONS FROM ERYTHROPOIETIC PROTOPORPHYRIA (EPP)

Foreign Priority and PCT Information for Patent: 8,334,265

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Australia	2006904745	Aug 31, 2006
Australia	2007900862	Feb 21, 2007

PCT Information
PCT Filed	August 31, 2007	PCT Application Number:	PCT/AU2007/001276
PCT Publication Date:	March 06, 2008	PCT Publication Number:	WO2008/025094

International Family Members for US Patent 8,334,265

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	2865422		300926	Netherlands
European Patent Office	2865422		LUC00062	Luxembourg
European Patent Office	2865422		CA 2018 00014	Denmark
European Patent Office	2865422		2018C/012	Belgium